PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

Overall these findings indicate that adding cabazitaxel to long-term androgen deprivation therapy and radiotherapy did not improve long-term outcomes and increased toxicity in men with high-risk ...

In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS ...

Phase 3 PEACE-2 data indicates that the addition of cabazitaxel to ADT plus RT did not improve clinical PFS in very high risk ...

While some of his allies have lamented that Biden's legacy as president has been reduced to questions of his declining health and mental acuity, many Democrats are still bitter about Biden's 2024 ...

Longtime friends and allies of former President Joe Biden are worried about the toll cancer treatment is taking on the 83-year-old, despite aides expressing optimism, those close to the former ...

The former president announced last year he has an aggressive form of prostate cancer. He and his aides say he’s doing well ...

Monsanto and thousands of people suing the company alleging its Roundup weedkiller caused them to develop cancer have reached a $7.25 billion settlement agreement. The proposed class action agreement ...

When James Choate-Deeds was diagnosed with prostate cancer, he joined a clinical trial for robotic-assisted surgery Wendy Grossman Kantor is an award-winning journalist who has contributed to PEOPLE ...

Contemporary guidelines recommend docetaxel as first-line chemotherapy for chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) who progress on an androgen receptor ...

“Talking about health should never be awkward,” the former NFL tight end tells PEOPLE Rob Gronkowski and Bruce Arians want you to “relax your tight ends.” The retired NFL star, 36, and former NFL ...

Because treatment of the whole prostate can lead to long-term side effects in patients with prostate cancer, interest in minimally invasive, focal treatment options has been growing for certain ...